Post hoc analysis suggests that BETMIGA™ may relieve overactive bladder symptoms where prior antimuscarinic treatment has failed

BETMIGA™ (mirabegron), a new oral treatment for overactive bladder, has the potential to provide relief for patients who have discontinued prior treatment due to insufficient efficacy or poor tolerability according to a post hoc analysis of the Phase III EU/Australian study.[1] The analysis investigated whether the benefits of mirabegron seen in a randomised, double-blind, placebo- and active-controlled Phase III study[2] were experienced by both treatment-naïve patients and those who had discontinued previous antimuscarinic treatment...